Cochrane · systematic review · CD001396
Selective serotonin reuptake inhibitors for premenstrual syndrome
Marjoribanks, J, Brown, J, O'Brien, PMS, et al. · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
Gynaecology and FertilityAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 2 · 28.6%Moderate 5 · 71.4%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
SSRIs for premenstrual syndrome: all symptoms (end scores)
Population: women with premenstrual syndrome
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Moderate dose SSRI versus placebo Luteal or continuous administration | no estimate extracted | 9 studies · 1276 participants | Low Downgraded: risk of bias, inconsistency |
Moderate dose SSRI versus placebo Luteal administration | no estimate extracted | 4 studies · 457 participants | Moderate Downgraded: inconsistency |
Moderate dose SSRI versus placebo Continuous administration | no estimate extracted | 7 studies · 843 participants | Low Downgraded: risk of bias, inconsistency |
SSRIs for premenstrual syndrome: all symptoms (change scores)
Population: women with premenstrual syndrome
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Moderate dose SSRI versus placebo Luteal administration2 | no estimate extracted | 4 studies · 657 participants | Moderate Downgraded: risk of bias |
SSRIs for premenstrual syndrome: withdrawal due to adverse effects
Population: women with premenstrual syndrome
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Low dose SSRI versus placebo Luteal or continuous administration | OR 1.76 [1.13, 2.75] | 7 studies · 1301 participants | Moderate Downgraded: risk of bias |
Mod dose SSRI versus placebo Luteal or continuous administration | OR 2.55 [1.84, 3.53] | 15 studies · 2447 participants | Moderate Downgraded: risk of bias, imprecision |
High dose SSRIs versus placebo Continuous administration | RR 6.35 [2.88, 14] | 1 study · 231 participants | Moderate Downgraded: risk of bias, imprecision |